Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (Nasdaq: INBS) reported its fiscal Q4 and full-year 2025 results, highlighting significant progress in its U.S. market expansion plans and operational performance. The company achieved 16% revenue growth both sequentially and year-over-year in Q4, reaching $843,884, driven by increased drug testing cartridge demand.

Key developments include advancement toward FDA 510(k) clearance for its opiate test system, expansion of its international presence to over 450 accounts across 24 countries, and a 24% year-over-year increase in cartridge sales for Q4. The company implemented operational efficiencies, launched multilingual support, and strengthened its intellectual property with a sixth U.S. patent.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference. The company's management team will present on Thursday, August 21, 2025, at 9:15 a.m. Eastern Time.

Investors can access the presentation through a webcast link and schedule one-on-one meetings with management through Sidoti representatives or KCSA Strategic Communications.

Intelligent Bio Solutions (Nasdaq: INBS) announced preliminary fiscal Q4 2025 results, highlighting 16% revenue growth both sequentially and year-over-year. The growth was driven by increased higher-margin cartridge sales and steady account expansion.

The company made significant operational progress, including submitting an FDA 510(k) application for its opiate test system for codeine. INBS also completed multilingual upgrades to its Intelligent Fingerprinting Drug Screening System and launched localized websites with enhanced CRM workflows across Europe, the Middle East, and Latin America.

Final audited results will be disclosed in the Annual Report on Form 10-K, expected during the week of August 11, 2025.

Intelligent Bio Solutions (Nasdaq: INBS) has submitted additional information to the FDA as part of its 510(k) clearance process for its fingerprint sweat-based drug screening technology. The submission includes extensive new cybersecurity and performance data, comprising 23 test reports and over 100 supporting attachments totaling more than 1900 pages.

The company invested 10,000 hours in data collection and conducted intensive cybersecurity testing, including penetration and electromagnetic compatibility testing. The technology's accuracy was reaffirmed using advanced quantification methods, including human eccrine sweat testing with an Ultra-Micro Balance scale.

Currently used across 450 accounts in 24 countries, INBS expects an FDA response within six weeks and aims to enter the multi-billion-dollar U.S. market in 2025, focusing initially on its opiate test system for codeine.

Intelligent Bio Solutions (Nasdaq: INBS) has secured a significant contract with a major London transport operator to implement its Intelligent Fingerprinting Drug Screening System across 14 operational sites serving over 4,400 staff. The transport operator manages a fleet of 1,400+ low-emission vehicles and serves more than one million passengers daily.

The company's drug testing technology is currently utilized by 450+ accounts across 24 countries through 18 distribution partners. INBS is actively expanding globally and pursuing FDA clearance for planned entry into the U.S. market in 2025.

Intelligent Bio Solutions (Nasdaq: INBS) has secured agreements to raise $3.8 million in gross proceeds through warrant exercises at a reduced price of $1.90 per share. The transaction involves current warrant holders exercising or prepaying existing warrants for 2,023,228 shares of common stock.

As part of the deal, participating holders will receive new Inducement Warrants for up to 4,046,456 shares at $1.90 per share, exercisable for 5.5 years after stockholder approval. The company plans to use the proceeds to complete its 510k filing with the FDA for its Fingerprint Drug Screening System and for working capital purposes. The transaction is expected to close around July 28, 2025.

Intelligent Bio Solutions (Nasdaq: INBS) announced new data strengthening its FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System. The company completed extensive cybersecurity and electromagnetic compatibility testing to validate system resilience. Using an Ultra-Micro Balance scale capable of measuring 0.0000001 grams, INBS confirmed its technology's ability to detect and analyze trace levels of fingerprint sweat.

The R&D team has invested over 6,000 hours into testing, data aggregation, analysis, and technical reporting. INBS currently supports more than 450 accounts across 24 countries with 18 distribution partners. The company plans to enter the U.S. market in 2025, pursuing FDA clearance for its opiate test system for codeine.

Intelligent Bio Solutions (Nasdaq: INBS) has signed a global distribution agreement with SMARTOX to distribute its SmarTest Patch drug detection product internationally, excluding the US and Canada. The partnership expands INBS's product portfolio in non-invasive drug testing solutions, specifically targeting justice and rehabilitation sectors.

The agreement builds on existing collaboration with SMARTOX, which currently distributes INBS's Intelligent Fingerprinting Drug Testing Solution in the US Forensic Use Only market. The global drug testing market is projected to reach $18.6 billion by 2030. INBS currently serves over 450 active accounts in 24 countries.

The company continues to pursue FDA clearance for its fingerprint sweat-based drug testing technology in the US market beyond Forensic Use Only applications.

Intelligent Bio Solutions (Nasdaq: INBS) has expanded its non-invasive drug testing portfolio with the addition of the SmarTest® Patch, a wearable device developed by SMARTOX®. The innovative patch enables continuous drug detection through sweat over 7-10 days and can detect substances including cocaine, opiates, methamphetamines, marijuana, and fentanyl.

The water-resistant and tamper-evident patch complements INBS's flagship Intelligent Fingerprinting Drug Testing Solution, offering customers flexibility in detection timeframes while maintaining a non-invasive approach. The product expansion particularly targets justice and rehabilitation settings outside the U.S., strengthening the company's position in the non-invasive testing market.